The OncoGenomics Explorer solution will provide Bayer with a centralized access to unified global genomics data for utilization across the entire research organization from target discovery to drug repositioning.
MediSapiens CEO Tommi Pisto said Big Data, a term invented for a collection of data sets so large and complex which became difficult to process using on-hand database management tools is becoming increasingly important in pharmaceutical research.
"Until now, the lack of software tools that can be adapted to various research environments has limited the full-scale use of this enormous reservoir of available data," Pisto added.
"OncoGenomics Explorer is our answer to this demand."